Étude de l'activité anti-cancéreuse du PCK3145, un peptide dérivé de PSP-94, sur les cancers hématologiques

摘要: PCK3145 has been shown to exert anti-tumor activity against prostate cancer cells. In a Phase I clinical study, this peptide demonstrated low toxicity. To determine whether could cytotoxic other marrow infiltrating cancers, we tested its hematologic cancers. Interestingly, inhibited the proliferation of human NHL (SR) and myeloma (RPMI-8226) cell lines murine mastocytoma (P815) line in vitro. Moreover, reduced clonogenicity these lines. explore vivo, DBA/2 mice were injected with P815 treatment significantly decreased tumors growth comparison PBS (p<0.001), scrambled (p<0.05) PCK5266 (amino acids 52-66 PSP94) (p<0.01). Intraperitoneal led number liver metastasis compared (p<0.05). MMP-9 levels, measured by ELISA, peripheral blood treated bearing similar those obtained healthy animals (12.83 1.890 (mean SD) ng/ml 6.48 0.4070 ng/ml, respectively), while levels elevated (35.12 8.559 22.60 3.944 respectively; p<0.05). NOD/SCID resulted significant inhibition SR (p<0.001) Consequently, can reduce tumor addition, potential inhibit cells dissemination lowering secretion. Thus, represents unique demonstrating sequence-specific malignancies.